We are committed to designing and developing innovative tools and techniques to identify novel therapeutic targets, delivery mechanisms, and bioactive molecules with high potential for industry uptake and clinical translation.
The Drug Discovery Initiative is built on collective expertise in drug discovery research from across the University, underpinned by state-of-the-art infrastructure and input from scientific advisory groups. We are a point of contact for internal researchers looking to connect with complementary capabilities in the area of drug discovery research, or for external stakeholders looking to engage with our researchers.
Through the Sydney Analytical Drug Discovery node, there are a suite of capabilities for the expression, purification and analysis of proteins of interest as targets.
This includes expression from bacterial, insect, and mammalian cells, X-ray crystallography and access to synchrotron protein crystallography.
Medicinal Chemistry is used to optimise the properties of the hit molecule.
Launching in 2024, MedChem Australia will integrate the expertise of three of the country’s leading medicinal chemistry groups (The Drug Discovery Initiative at the University of Sydney, in collaboration with the Monash Institute of Pharmaceutical Sciences, WEHI) and Therapeutics Innovation Australia to establish a national framework for translating discoveries into optimised drug candidates.
The Drug Discovery Initiative is led by its Academic Director, Prof Michael Kassiou. Michael is currently a Professor of Medicinal Chemistry at the University and an NHMRC Principal Research Fellow. He has been awarded several prizes including the Adrien Albert Award in Medicinal Chemistry and the RACI Applied Research Medal in 2020, and is Chief Editor for the journal Frontiers in Medicinal and Pharmaceutical Chemistry and Associate Editor for ACS Chemical Neuroscience.